13.12.2017 • News

PMC Buys Isochem’s Pharma Business

(c) SFIO CRACHO/Shutterstock
(c) SFIO CRACHO/Shutterstock

PMC Group France, a wholly owned subsidiary of US-based PMC Group International, has acquired the pharmaceuticals business of France’s Isochem for an undisclosed sum.

The business comprises research, product and process development capabilities as well as pilot-scale and full plant-scale production of drug intermediates and APIs for major companies worldwide.

Isochem operates three sites at Gennevilliers, Pithiviers and Vert-le-Petit, all within a 60-mile radius of Paris and audited by the US Food and Drug Administration (FDA) as cGMP-compliant.

Going forward, the company will be known as PMC Isochem, operating as a wholly owned subsidiary of PMC Group France.

The acquisition follows the October purchase of Indian pharma Yegna Manojavam Drugs and Chemicals by PMC Group subsidiary, PMC YM-Pharma. The Indian company’s cGMP plant is claimed to be one of the largest fluoroquinolone drug manufacturing facilities in France.

Expert Insights

ADCs for Precision Cancer Therapy
Comprehensive Insights into Antibody–Drug Conjugates

ADCs for Precision Cancer Therapy

Explore how antibody-drug conjugates are reshaping precision cancer therapy and discover what it takes to successfully develop, manufacture, and scale these complex biologics.

Free Virtual Event

Batteries and Hydrogen: Competitors or Partners?
CHEManager Spotlight

Batteries and Hydrogen: Competitors or Partners?

17 September 2026 | Reserve your spot to learn where solid-state batteries and green hydrogen are headed—and how leading teams are turning them into scalable energy storage solutions.

most read

Photo

VCI Welcomes US-EU Customs Deal

The German Chemical Industry Association (VCI) welcomes the fact that Ursula von der Leyen, President of the European Commission, and US President Donald Trump have averted the danger of a trade war for the time being.